Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Mar 4;310(6979):575–579. doi: 10.1136/bmj.310.6979.575

Drug treatment of Parkinson's disease.

N Quinn 1
PMCID: PMC2548944  PMID: 7888935

Abstract

A wide variety of drugs is available for treating Parkinson's disease, including anticholinergics, amantadine levodopa, dopamine agonists, and selegiline. In younger patients (less than 50) levodopa is usually delayed provided that adequate relief of symptoms can be achieved with other drugs. In older patients (greater than 70) levodopa should be started as soon as symptom relief is required. Between these ages there is no consensus, but at present most such patients should probably be given controlled release levodopa before a dopamine agonist is added. Fluctuations can often be alleviated by giving controlled release preparations of levodopa, by giving small doses at frequent intervals, by adding selegiline or a long acting oral agonist, or by subcutaneous apomorphine. Dyskinesia can be peak dose, diphasic, or "off period." The diphasic form is hardest to alleviate. Psychiatric side effects should initially be managed by changing the antiparkinsonian treatment before resorting to antipsychotic drugs.

Full text

PDF
575

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergamasco B., Benna P., Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand. 1990 May;81(5):383–387. doi: 10.1111/j.1600-0404.1990.tb00980.x. [DOI] [PubMed] [Google Scholar]
  2. Dubois B., Danzé F., Pillon B., Cusimano G., Lhermitte F., Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol. 1987 Jul;22(1):26–30. doi: 10.1002/ana.410220108. [DOI] [PubMed] [Google Scholar]
  3. Friedman J. H., Lannon M. C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 1989 Sep;39(9):1219–1221. doi: 10.1212/wnl.39.9.1219. [DOI] [PubMed] [Google Scholar]
  4. Goetz C. G., De Long M. R., Penn R. D., Bakay R. A. Neurosurgical horizons in Parkinson's disease. Neurology. 1993 Jan;43(1):1–7. doi: 10.1212/wnl.43.1_part_1.1. [DOI] [PubMed] [Google Scholar]
  5. Hely M. A., Morris J. G., Rail D., Reid W. G., O'Sullivan D. J., Williamson P. M., Genge S., Broe G. A. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):324–328. doi: 10.1136/jnnp.52.3.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hughes A. J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A. J., Stern G. M. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993 Apr;8(2):165–170. doi: 10.1002/mds.870080208. [DOI] [PubMed] [Google Scholar]
  7. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991 Feb;41(2 ):202–205. doi: 10.1212/wnl.41.2_part_1.202. [DOI] [PubMed] [Google Scholar]
  8. Lhermitte F., Agid Y., Signoret J. L. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol. 1978 May;35(5):261–263. doi: 10.1001/archneur.1978.00500290007002. [DOI] [PubMed] [Google Scholar]
  9. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  10. Montastruc J. L., Rascol O., Senard J. M., Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1034–1038. doi: 10.1136/jnnp.57.9.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mouradian M. M., Heuser I. J., Baronti F., Chase T. N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 1990 Jan;27(1):18–23. doi: 10.1002/ana.410270105. [DOI] [PubMed] [Google Scholar]
  12. Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 1987 Nov;17(4):899–904. doi: 10.1017/s0033291700000702. [DOI] [PubMed] [Google Scholar]
  13. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
  14. Nutt J. G., Woodward W. R., Hammerstad J. P., Carter J. H., Anderson J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488. doi: 10.1056/NEJM198402233100802. [DOI] [PubMed] [Google Scholar]
  15. Pincus J. H., Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology. 1988 Mar;38(3):481–483. doi: 10.1212/wnl.38.3.481. [DOI] [PubMed] [Google Scholar]
  16. Poewe W. H., Lees A. J., Stern G. M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol. 1988 Jan;23(1):73–78. doi: 10.1002/ana.410230112. [DOI] [PubMed] [Google Scholar]
  17. Quinn N., Critchley P., Marsden C. D. Young onset Parkinson's disease. Mov Disord. 1987;2(2):73–91. doi: 10.1002/mds.870020201. [DOI] [PubMed] [Google Scholar]
  18. Riley D. E., Lang A. E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology. 1993 Aug;43(8):1459–1464. doi: 10.1212/wnl.43.8.1459. [DOI] [PubMed] [Google Scholar]
  19. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
  20. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 1989 Mar;39(3):336–339. doi: 10.1212/wnl.39.3.336. [DOI] [PubMed] [Google Scholar]
  21. Roberts J. W., Cora-Locatelli G., Bravi D., Amantea M. A., Mouradian M. M., Chase T. N. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 1993 Dec;43(12):2685–2688. doi: 10.1212/wnl.43.12.2685. [DOI] [PubMed] [Google Scholar]
  22. Swanson P. D. Drug treatment of Parkinson's disease: is "polypharmacy" best? J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):401–403. doi: 10.1136/jnnp.57.4.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weiner W. J., Factor S. A., Sanchez-Ramos J. R., Singer C., Sheldon C., Cornelius L., Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 1993 Jan;43(1):21–27. doi: 10.1212/wnl.43.1_part_1.21. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES